menu
    • menu

    Company profile for Anchiano Therapeutics, Inc

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinica...
    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Anchiano Therapeutics, IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Kendall Square, Building 600, Suite 6-106, Cambridge, MA 02139
    Telephone
    Telephone
    857-259-4622
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.anchiano.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anchiano/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anchiano Announces Shareholder Approval of the Merger with Chemomab
    Anchiano Announces Shareholder Approval of the Merger with Chemomab

    15 Mar 2021

    // BIOSPACE

    https://www.biospace.com/article/releases/anchiano-announces-shareholder-approval-of-the-merger-with-chemomab-and-prices-45-5m-private-financing/?s=79

    BIOSPACE
    15 Mar 2021
    Share Share
    Anchiano and Chemomab Announce Entry Into Merger Agreement
    Anchiano and Chemomab Announce Entry Into Merger Agreement

    15 Dec 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/12/15/2145458/0/en/Anchiano-Therapeutics-and-Chemomab-Announce-Entry-Into-Definitive-Merger-Agreement.html

    GLOBENEWSWIRE
    15 Dec 2020
    Share Share
    Anchiano Appoints Steve DiPalma as Chief Financial Officer
    Anchiano Appoints Steve DiPalma as Chief Financial Officer

    05 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/05/2028022/0/en/Anchiano-Appoints-Steve-DiPalma-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    05 May 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search